Network module analysis and molecular docking-based study on the mechanism of astragali radix against non-small cell lung cancer

Abstract excerpt

BACKGROUND: Most lung cancer patients worldwide (stage IV non-small cell lung cancer, NSCLC) have a poor survival: 25%-30% patients die < 3 months. Yet, of those surviving > 3 months, 10%-15% patients survive (very) long. Astragali radix (AR) is an effective traditional Chinese medicine widely used for non-small cell lung cancer (NSCLC). However, the pharmacological mechanisms of AR on NSCLC remain to be...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bioinformatics and Genomic Networks
• Share to Computational Drug Discovery Methods
• Share to Traditional Chinese Medicine Analysis